Information provided to me by an old friend and RA, named Mitchel A., in California
Thu Oct 14, 2010 3:21pm EDT
* Five-year follow-up data consistent with four-year data
* No new cases of serious side effects were reported
* Genzyme sees drug as more valuable than Sanofi does (Adds description of disease, analyst comment, side effect details)
By Toni Clarke
BOSTON, Oct 14 (Reuters) – Genzyme Corp (GENZ.O) presented new data from a trial of its experimental multiple sclerosis drug alemtuzumab on Thursday that continued to show strong efficacy with no new or worsening side effects.
Genzyme believes the drug, if approved, could become the new standard of care for treating the disease and gain a significant portion of a market the company estimates will be worth roughly $13 billion by the end of this year.
Alemtuzumab, also known as Campath, is a key pawn in the battle between Genzyme and
***********************************************************
“Providing You with ‘MS Views and News’, is what we do“
Keep Informed and up–to–date with information concerning
Multiple Sclerosis when registered at
the MS Views and News website.
****************************************************************
Disclaimer: ‘MS Views and News’ (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
. ****************************************************************
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews